C2N Diagnostics’ PrecivityAD2 becomes first FDA-cleared Alzheimer’s blood test for adults aged 40+
PrecivityAD2 is designed to be used alongside a clinical assessment to help healthcare professionals identify patients with amyloid pathology associated with Alzheimer’s disease






_(1).jpeg)













